Resistance
By: Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, Patrick Marcellin, MD, Norah Terrault, MD, MPH
|
Expert clinicians discuss key findings on hepatitis B virus therapy from the 43rd Annual Meeting of the European Association for the Study of the Liver
Date Posted: 7/3/2008
|
By: Ira M. Jacobson, MD
|
Join Ira M. Jacobson, MD, as he reviews the latest data on which HBV therapy to choose, when to change, and when to stop.
Date Posted: 6/25/2008
|
By: Robert S. Brown, Jr., MD, MPH, Tram T. Tran, MD
|
Tram T. Tran, MD, and Robert S. Brown, Jr., MD, MPH, discuss new agents for the treatment of chronic hepatitis B and how they might fit in the treatment landscape.
Date Posted: 6/24/2008
|
By: Daniel Shouval, MD
|
Daniel Shouval, MD, provides an update on the latest management strategies for patients with chronic hepatitis B.
Date Posted: 6/18/2008
|
 |
Download and review key data selected by Daniel Shouval, MD on clinical HBV data that was presented at the 2008 EASL meeting in Milan. Use the slides in your own presentations!
File Format: Microsoft PowerPoint (.ppt) | File Size: 948 KB
Date Posted: 5/9/2008
|
|
Results of Japanese studies (ETV-047, ETV-053, ETV-060) reveal that treatment with entecavir is both safe and effective for up to 3 years, and a higher barrier to resistance is maintained in treatment-naive chronic hepatitis B patients
Date Posted: 4/29/2008
|
|
Tenofovir safe and effective at decreasing HBV DNA and returning ALT levels to normal in both lamivudine-naive and lamivudine-experienced patients with chronic hepatitis B, without appearance of resistance
Date Posted: 4/26/2008
|
By: Emmet B. Keeffe, MD, MACP, Fred Poordad, MD, Paul Martin, MD
|
Emmet B. Keeffe, MD, MACP; Fred Poordad, MD; and Paul Martin, MD, discuss important clinical data presented on patients with chronic hepatitis B virus infection at the 2007 liver disease meeting in Boston.
Date Posted: 1/9/2008
|
|
Featured Content
Expert faculty members review the most important advances in hepatitis and its mgmt in 2008.
Join our experts as they review treatment options for patients with nonresponse to HCV therapy.
2008 Independent Conference Report on Hepatitis B and C Virus Resistance to Antiviral Therapies.
|